• When Context Changes What E-64 Results Mean

  2026-10-19

  The Dahl salt-sensitive rat study did not find that chronic E-64 treatment altered salt-driven hypertension, albuminuria, podocyte basal calcium, or reported renal injury under the study conditions. Its value lies not in establishing that cysteine cathepsins are biologically irrelevant, but in showing how target engagement, inhibitor breadth, disease model, comparator, and endpoint selection constrain the meaning of a negative result.

• Sodium Orthovanadate: Identity, Mechanism and Limits

  2026-10-19

  APExBIO describes Sodium Orthovanadate (Na3VO4) as a broadly acting, reversible inhibitor of protein tyrosine phosphatases, alkaline phosphatase and ATPase-related enzymes. Its documented role is to modify the enzymatic context in which phosphorylation or energy-metabolism measurements are interpreted, but no identity-matched research paper or quantitative performance evidence is available here.

• Nocodazole and the Cellular Entry of Spiroplasma

  2026-10-18

  Wei et al. used Drosophila S2 cells to examine how Spiroplasma eriocheiris enters and affects host cells. Their findings implicated clathrin-mediated endocytosis, macropinocytosis, and the actin–microtubule cytoskeleton, while also showing that nocodazole-sensitive reductions in intracellular bacterial copy number cannot by themselves distinguish impaired entry from altered trafficking, replication, survival, or host-cell physiology.

• 2-NBDG Assay: Mechanism and Evidence Boundaries

  2026-10-17

  The APExBIO product page identifies K2212 as a non-radioactive fluorescent assay based on 2-NBDG, but no identity-matched study is available to establish performance, effect sizes, or application-specific validity.

• When E-64 Results Change Meaning Across Models

  2026-10-16

  A result from E-64 research cannot be separated from its model, comparator, molecular target, and readout. In Dahl salt-sensitive rats, chronic cysteine cathepsin inhibition was associated with evidence of target engagement but did not alter hypertension, albuminuria, podocyte calcium, or reported renal injury. The study therefore narrows a disease-specific claim rather than disproving cathepsin biology generally. This editorial examines how biochemical inhibition, pharmacodynamic markers, and physiological outcomes can diverge, and why those distinctions define the limits of interpretation.

• Etazolate Hydrochloride: Evidence Boundaries

  2026-10-16

  The available APExBIO listing identifies Etazolate hydrochloride as catalog product B6304, but it supplies no product description or identity-matched research evidence. Accordingly, a defensible scientific overview can address catalog identity and evidence boundaries, but not a molecular mechanism, assay interpretation, biological activity, or comparative performance.

• Fluorescein-12-dUTP: What Is Documented

  2026-10-15

  APExBIO identifies Fluorescein-12-dUTP as product B8207, but the available product record provides no description and no identity-matched research study is available. The chemical name supports a cautious, class-level interpretation: a fluorescently labeled deoxyuridine triphosphate intended, in principle, to connect nucleotide incorporation with an optical readout. That interpretation does not establish product-specific incorporation, assay performance, specificity, or suitability for any application.

• How MLN2238 Reveals the CRTC–CREB Stress Axis

  2026-10-15

  The cited study used MLN2238 as a proteasome-inhibition perturbation to identify a ROS–JNK–CRTC/CREB response to proteotoxic stress in Drosophila. Its evidence supports a mechanistic model in which proteasome dysfunction activates protective transcriptional programs, while the fly and cell-based systems limit direct conclusions about human disease, oncology, or clinical treatment.

• Protease Inhibitor Cocktail: Evidence and Scope

  2026-10-14

  The APExBIO product page identifies K4007 as an EDTA-free, 100X aqueous protease inhibitor cocktail, but it does not disclose composition, target spectrum, assay data, or identity-matched research. Its mechanism can therefore be discussed only at the level of general protease inhibition, while claims about performance, compatibility, or application-specific efficacy remain unsupported.

• 7-Dehydrocholesterol: What the Evidence Shows

  2026-10-14

  7-Dehydrocholesterol is a sterol intermediate linking cholesterol metabolism with vitamin D biology. A 2026 grass carp study associated dhcr7 disruption with greater resistance to GCRV-II, but the findings concern genetic alteration in one fish species—not 7-dehydrocholesterol supplementation, antiviral treatment, or evidence applicable to humans.

• E-64 in Salt-Sensitive Hypertension: What the Study Shows

  2026-10-13

  A 2016 rat study found that chronic E-64 exposure did not alter hypertension, albuminuria, or basal podocyte calcium in a Dahl salt-sensitive model. The result is informative but limited to this animal model and to broad cysteine protease inhibition under the reported conditions.

• Phosbind Biotin LC: Evidence and Scope

  2026-10-13

  Phosbind Biotin LC is a supplier-described phosphate-binding reagent for sequence-independent phosphorylated protein detection on PVDF membranes. The available evidence establishes product identity and intended conceptual use, but does not independently verify sensitivity, specificity, performance, or broader applicability.

• E-64d and the Limits of Cell-Death Inference

  2026-10-12

  The supplied study evaluates MEDUSA, a modeling framework for separating drug-associated changes in cellular growth and death rates. Its findings clarify how p53 status can influence DNA-damage-induced death in the studied cell models, but they do not establish a role for E-64d, calpain, or cathepsins in that mechanism. Supplier-described uses of E-64d therefore require cautious interpretation and cannot substitute for target-specific genetic or biochemical evidence.

• Sulfo-NHS-LC-Biotin: Identity and Scope

  2026-10-12

  Sulfo-NHS-LC-Biotin, also identified as sulfosuccinimidyl-6-(biotinamido) hexanoate, is documented by APExBIO as a water-compatible reagent for covalent biotin labeling of accessible primary amines. The available evidence is limited to supplier information: no matched research paper was provided, so performance claims, comparative advantages, quantitative outcomes, and broader biological applicability cannot be independently assessed here.

• Lysoptosis and the Limits of Protease Inference

  2026-10-11

  Luke et al. present lysoptosis as a distinct, evolutionarily conserved lysosome-dependent cell-death pathway revealed by loss of intracellular serpin protection. The evidence supports a role for lysosomal membrane permeabilization and cathepsin-dependent proteolysis, while leaving broader tissue, disease and therapeutic applicability unresolved.

8014 records 1/535 page Next 12345 下5页 Last page